IMGN Price Targets and Analyst Ratings NASDAQ:IMGN
IMGN Forecast. What You Should Know.
IMGN Historical Ratings and Targets
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and... Read more
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.